- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04366622
Study on the Safety of BAY 63-2521, How it is Tolerated and the Way the Body Absorbs, Distributes and Gets Rid of the Study Drug Given as a Single Oral Dose of 1 mg Tablet in Participants With Impaired Liver Function and Healthy Participants Matched for Age-, Gender-, and Weight
April 25, 2020 updated by: Bayer
Investigation of Pharmacokinetics, Safety, and Tolerability of BAY 63-2521 in Male and Female Subjects With Hepatic Impairment (Classified as Child Pugh A or B) and in Age-, Weight- and Gender-matched Healthy Subjects Following a Single Oral Dose of 1 mg BAY 63-2521 in a Single-center, Non-randomized, Non-controlled, Non-blinded, Observational Study With Group Stratification
BAY 63-2521 is intended to be used for a disease that affects the blood flow through the lungs.
Renal impairment is a common condition in patients with this disease.
The goal of the study is to learn more about the safety of BAY 63-2521, how it is tolerated and the way the body absorbs, distributes and gets rid of the study dug given as a single oral dose of 1 mg tablet in participants with renal impairment and healthy participants matched for age-, gender-, and weight
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
32
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Schleswig-Holstein
-
Kiel, Schleswig-Holstein, Germany, 24105
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 79 years (ADULT, OLDER_ADULT)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
All
Description
Inclusion criteria for all subjects:
- Male and female White subjects 18 to ≤79 years of age, BMI between 18 and 34 kg/m^2
- Women without childbearing potential or with childbearing potential but only if the pregnancy test is negative and are under highly effective contraception
Inclusion criteria for subjects with liver cirrhosis:
- Documented liver cirrhosis confirmed by histopathology, eg previous liver biopsy, laparoscopy, or ultrasound Hepatic impairment (Child Pugh A or B)
- Stable liver disease
Inclusion criteria for healthy subjects:
- Age- (+/-10 years), weight- (+/-10 kg body weight), and gender-matched to a subject with liver cirrhosis as far as possible
Exclusion criteria for all subjects:
- Febrile illness within 1 week before the start of the study
- Hypersensitivity to riociguat and / or to inactive constituents
- Smoking
Exclusion criteria for subjects with liver cirrhosis:
- Hemoglobin <8 g/dL
- Severe cerebrovascular or cardiac disorders, eg myocardial infarction less than 6 months prior to dosing, congestive heart failure of NYHA grade III or IV, severe arrhythmia requiring antiarrhythmic treatment
- Evidence of hepatic encephalopathy related to chronic liver disease > Grade II
- Renal failure with a creatinine clearance <40 mL/min
- Resting heart rate in the awake subject below 45 BPM or above 100 BPM
- Systolic blood pressure (SBP) below 100 mmHg or above 160 mmHg, Diastolic blood pressure (DBP) above 95 mmHg
- Platelet count <30 x 10^9/L
- History of bleeding within the past 3 months
- AP >4 times the upper limit of normal (ULN)
- AST or ALT in conjunction with GGT >= 4 times the ULN (an isolated elevation of GGT >4 times ULN did not exclude the subject)
- Serum albumin <20 g/L
- Diabetes mellitus with a fasting blood glucose >220 mg/dL or HbA1c >10%
- Prothrombin time (Quick test) <30%
- Subjects who had undergone porto-caval shunt surgery
- Use of medications known to interfere with hepatic metabolism (eg cimetidine, barbiturates, phenothiazines, etc) or known to alter other major organs or systems within 30 days prior to dosing
- Severe infection, malignancy, psychosis, or any clinically significant illness within 4 weeks prior to dosing
- Concomitant use of any medication except medications necessary for the treatment of the kidney disease or related complications
- Concomitant use of phosphodiesterase-5 inhibitors, endothelin receptor antagonists (ERAs, eg bosentan), intravenous or inhalative prostacyclins, or nitrates
- Concomitant use of potent CYP3A4 and P-gp inhibitors
Exclusion criteria for healthy subjects:
- Conspicuous findings in medical history or pre-study examination
- History of relevant diseases of vital organs, central nervous system, or other organs
- Resting heart rate in the awake subject below 45 BPM or above 90 BPM
- SBP below 100 mmHg or above 145 mmHg, DBP above 95 mmHg
- Regular daily consumption of more than 1 liter of usual beer or the equivalent quantity of approximately 40 g of alcohol in another form
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: BASIC_SCIENCE
- Allocation: NON_RANDOMIZED
- Interventional Model: PARALLEL
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Riociguat, Child Pugh A
Participants with liver cirrhosis and mild hepatic impairment received a single dose of 1 mg (2 x 0.5 mg IR tablet) of riociguat in the fasted state
|
0.5 mg riociguat as an immediate-release (IR) tablet
|
EXPERIMENTAL: Riociguat, Child Pugh B
Participants with liver cirrhosis and moderate hepatic impairment received a single dose of 1 mg (2 x 0.5 mg IR tablet) of riociguat in the fasted state
|
0.5 mg riociguat as an immediate-release (IR) tablet
|
EXPERIMENTAL: Riociguat, control A
Healthy age-, weight-, and gender- matched participants to Child Pugh A group received a single dose of 1 mg (2 x 0.5 mg IR tablet) of riociguat in the fasted state
|
0.5 mg riociguat as an immediate-release (IR) tablet
|
EXPERIMENTAL: Riociguat, control B
Healthy age-, weight-, and gender- matched participants to Child Pugh B group received a single dose of 1 mg (2 x 0.5 mg IR tablet) of riociguat in the fasted state
|
0.5 mg riociguat as an immediate-release (IR) tablet
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
AUC
Time Frame: Pre-dose and up to 72 hours post-dose, additionally up to 96 hours post-dose for Child Pugh B group only
|
Area under the plasma concentration vs time curve from zero to infinity for total (bound and unbound) drug after single dose for BAY 63-2521 and its metabolite M1 (BAY 60-4552)
|
Pre-dose and up to 72 hours post-dose, additionally up to 96 hours post-dose for Child Pugh B group only
|
Cmax
Time Frame: Pre-dose and up to 72 hours post-dose, additionally up to 96 hours post-dose for Child Pugh B group only
|
Maximum total (bound and unbound) drug concentration in plasma after single dose administration for BAY 63-2521 and its metabolite M1
|
Pre-dose and up to 72 hours post-dose, additionally up to 96 hours post-dose for Child Pugh B group only
|
t½
Time Frame: Pre-dose and up to 72 hours post-dose, additionally up to 96 hours post-dose for Child Pugh B group only
|
Half-life associated with the terminal slope for BAY 63-2521 and its metabolite M1
|
Pre-dose and up to 72 hours post-dose, additionally up to 96 hours post-dose for Child Pugh B group only
|
fu
Time Frame: From 2 hours post-dose up to 24 hours post-dose
|
Fraction unbound for BAY 63-2521 and its metabolite M1
|
From 2 hours post-dose up to 24 hours post-dose
|
AUCu
Time Frame: From 2 hours post-dose up to 24 hours post-dose
|
AUC for unbound drug for BAY 63-2521 and its metabolite M1
|
From 2 hours post-dose up to 24 hours post-dose
|
Cmax,u
Time Frame: From 2 hours post-dose up to 24 hours post-dose
|
Cmax for unbound drug for BAY 63-2521 and its metabolite M1
|
From 2 hours post-dose up to 24 hours post-dose
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of participants with adverse events
Time Frame: Approximately 5 weeks
|
Approximately 5 weeks
|
|
AUC/D
Time Frame: Pre-dose and up to 72 hours post-dose, additionally up to 96 hours post-dose for Child Pugh B group only
|
AUC divided by dose (mg) for BAY 63-2521 and its metabolite M1
|
Pre-dose and up to 72 hours post-dose, additionally up to 96 hours post-dose for Child Pugh B group only
|
AUCnorm
Time Frame: Pre-dose and up to 72 hours post-dose, additionally up to 96 hours post-dose for Child Pugh B group only
|
AUC divided by dose (mg) per kg body weight for BAY 63-2521 and its metabolite M1
|
Pre-dose and up to 72 hours post-dose, additionally up to 96 hours post-dose for Child Pugh B group only
|
AUCu,norm
Time Frame: From 2 hours post-dose up to 24 hours post-dose
|
AUCnorm for unbound drug for BAY 63-2521 and its metabolite M1
|
From 2 hours post-dose up to 24 hours post-dose
|
AUC(0-tlast)
Time Frame: Pre-dose and up to 72 hours post-dose, additionally up to 96 hours post-dose for Child Pugh B group only
|
AUC from time 0 to the last data point for BAY 63-2521 and its metabolite M1
|
Pre-dose and up to 72 hours post-dose, additionally up to 96 hours post-dose for Child Pugh B group only
|
Cmax/D
Time Frame: Pre-dose and up to 72 hours post-dose, additionally up to 96 hours post-dose for Child Pugh B group only
|
Cmax divided by dose (mg) for BAY 63-2521 and its metabolite M1
|
Pre-dose and up to 72 hours post-dose, additionally up to 96 hours post-dose for Child Pugh B group only
|
Cmax,norm
Time Frame: Pre-dose and up to 72 hours post-dose, additionally up to 96 hours post-dose for Child Pugh B group only
|
Cmax divided by dose (mg) per kg body weight for BAY 63-2521 and its metabolite M1
|
Pre-dose and up to 72 hours post-dose, additionally up to 96 hours post-dose for Child Pugh B group only
|
Cmax,u,norm
Time Frame: From 2 hours post-dose up to 24 hours post-dose
|
Cmax,norm for unbound drug for BAY 63-2521 and its metabolite M1
|
From 2 hours post-dose up to 24 hours post-dose
|
tmax
Time Frame: Pre-dose and up to 72 hours post-dose, additionally up to 96 hours post-dose for Child Pugh B group only
|
Time to reach maximum drug concentration in plasma after single dose for BAY 63-2521 and its metabolite M1
|
Pre-dose and up to 72 hours post-dose, additionally up to 96 hours post-dose for Child Pugh B group only
|
MRT
Time Frame: Pre-dose and up to 72 hours post-dose, additionally up to 96 hours post-dose for Child Pugh B group only
|
Mean residence time for BAY 63-2521 and its metabolite M1
|
Pre-dose and up to 72 hours post-dose, additionally up to 96 hours post-dose for Child Pugh B group only
|
CL/F
Time Frame: Pre-dose and up to 72 hours post-dose, additionally up to 96 hours post-dose for Child Pugh B group only
|
Total body clearance of total (bound and unbound) drug from plasma calculated after oral administration (apparent oral clearance) for BAY 63-2521 and its metabolite M1
|
Pre-dose and up to 72 hours post-dose, additionally up to 96 hours post-dose for Child Pugh B group only
|
CLu/F
Time Frame: From 2 hours post-dose up to 24 hours post-dose
|
CL/F for unbound drug for BAY 63-2521 and its metabolite M1
|
From 2 hours post-dose up to 24 hours post-dose
|
Vz/F
Time Frame: Pre-dose and up to 72 hours post-dose, additionally up to 96 hours post-dose for Child Pugh B group only
|
Apparent volume of distribution during terminal phase after oral administration for BAY 63-2521 and its metabolite M1
|
Pre-dose and up to 72 hours post-dose, additionally up to 96 hours post-dose for Child Pugh B group only
|
AE,ur
Time Frame: Pre-dose and up to 72 hours post-dose
|
Amount of (total) drug excreted in urine for BAY 63-2521 and its metabolite M1
|
Pre-dose and up to 72 hours post-dose
|
CLR
Time Frame: Pre-dose and up to 72 hours post-dose
|
Renal body clearance of drug for BAY 63-2521 and its metabolite M1
|
Pre-dose and up to 72 hours post-dose
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
April 14, 2010
Primary Completion (ACTUAL)
April 28, 2011
Study Completion (ACTUAL)
September 15, 2011
Study Registration Dates
First Submitted
April 23, 2020
First Submitted That Met QC Criteria
April 25, 2020
First Posted (ACTUAL)
April 29, 2020
Study Record Updates
Last Update Posted (ACTUAL)
April 29, 2020
Last Update Submitted That Met QC Criteria
April 25, 2020
Last Verified
April 1, 2020
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 15001
- 2009-017684-42 (EUDRACT_NUMBER)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
UNDECIDED
IPD Plan Description
Availability of this study's data will be determined according to Bayer's commitment to the EFPIA/PhRMA "Principles for responsible clinical trial data sharing".
This pertains to scope, timepoint and process of data access.
As such, Bayer commits to sharing upon request from qualified researchers patient-level clinical trial data, study-level clinical trial data, and protocols from clinical trials in patients for medicines and indications approved in the US and EU as necessary for conducting legitimate research.
This applies to data on new medicines and indications that have been approved by the EU and US regulatory agencies on or after January 01, 2014.
Interested researchers can use www.clinicalstudydatarequest.com to request access to anonymized patient-level data and supporting documents from clinical studies to conduct research.
Information on the Bayer criteria for listing studies and other relevant information is provided in the Study sponsors section of the portal.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Clinical Pharmacology
-
BayerCompletedClinical PharmacologyGermany
-
BayerJanssen Research & Development, LLCCompleted
-
Guangzhou Lupeng Pharmaceutical Company LTD.Completed
-
BayerJanssen Research & Development, LLCCompleted
-
BayerCompleted
-
Solvay PharmaceuticalsCompletedPharmacology, ClinicalNetherlands
-
TakedaCompleted
-
Cinfa BiotechCompletedClinical PharmacologyGermany
-
BayerCompleted
Clinical Trials on Riociguat (Adempas, BAY 63-2521)
-
BayerCompleted
-
Danish Headache CenterNot yet recruitingMigraine Without AuraDenmark
-
International CTEPH AssociationTerminatedChronic Thromboembolic Pulmonary Hypertension | CTEPHGermany, United States, United Kingdom, France
-
BayerCompletedPulmonary Disease, Chronic Obstructive | Hypertension, PulmonaryGermany
-
BayerCompletedHypertension, PulmonaryTurkey, Austria, Czechia, Russian Federation, Slovakia, Switzerland, Italy, Germany, United Kingdom, France, Belgium, Canada, Colombia, Greece, Luxembourg, Netherlands, Spain, Taiwan, Denmark, Sweden, Argentina, Portugal, Saudi Arabia, Austral... and more
-
BayerRecruitingHypertension, PulmonaryFrance, Italy, Korea, Republic of, Poland, Thailand
-
BayerActive, not recruiting
-
BayerCompletedPulmonary HypertensionBelgium, France, Spain, Turkey, Portugal, Taiwan, Japan, United States, Switzerland, Korea, Republic of, Austria, Canada, China, Denmark, Germany, Mexico, Russian Federation, Argentina, Italy, Poland, Australia, Brazil, Czechia, United... and more
-
BayerCompletedPulmonary HypertensionBelgium, France, Spain, Turkey, Portugal, Taiwan, Japan, United States, Switzerland, Korea, Republic of, Austria, Canada, China, Denmark, Germany, Russian Federation, Mexico, Argentina, Netherlands, Italy, Poland, United Kingdom, Au... and more
-
BayerCompletedScleroderma, SystemicNetherlands, Belgium, United States, Australia, Hungary, United Kingdom, Canada, Germany, Switzerland, France, Italy, Japan, New Zealand, Turkey, Czechia